Supplementary Figure S2 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations

Vivek Subbiah; Vaibhav Sahai; Dejan Maglic; Kamil Bruderek; B. Barry Touré; Songping Zhao; Roberto Valverde; Patrick J. O’Hearn; Demetri T. Moustakas; Heike Schönherr; Nastaran Gerami-Moayed; Alexander M. Taylor; Brandi M. Hudson; Damian J. Houde; Debjani Pal; Lindsey Foster; Hakan Günaydin; Pelin Ayaz; Dina A. Sharon; Lipika Goyal; Alison M. Schram; Suneel Kamath; Cori Ann Sherwin; Oleg Schmidt‐Kittler; Kai Yu Jen; Fabien Ricard; Beni B. Wolf; David E. Shaw; Donald A. Bergstrom; James Watters; Jessica B. Casaletto

doi:10.1158/2159-8290.27025769.v1

Abstract

Supplementary Figure 2. Treatment with RLY-4008 is well-tolerated and leads to dose-dependent inhibition of FGFR2 and tumor regression in multiple FGFR2-altered tumor models.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Subbiah et al. (2024) studied this question.

synapsesocial.com/papers/68e586b5b6db643587522f07 https://doi.org/10.1158/2159-8290.27025769.v1

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S2 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations

Abstract

Discussion

Cite This Study

Supplementary Figure S2 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations

Abstract

Discussion

Cite This Study

Keep reading

Keep reading